Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Mayo Clinic National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00654160 |
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with fluorouracil and leucovorin in treating patients with advanced gastrointestinal cancer.
Condition | Intervention | Phase |
---|---|---|
Anal Cancer Carcinoma of the Appendix Colorectal Cancer Esophageal Cancer Extrahepatic Bile Duct Cancer Gallbladder Cancer Gastric Cancer Gastrointestinal Carcinoid Tumor Gastrointestinal Stromal Tumor Liver Cancer Pancreatic Cancer Small Intestine Cancer |
Drug: fluorouracil Drug: irinotecan hydrochloride Drug: leucovorin calcium Other: pharmacogenomic studies Other: pharmacological study |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer |
Estimated Enrollment: | 70 |
Study Start Date: | June 2008 |
Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a dose-escalation study of irinotecan hydrochloride. Patients are stratified according to genotype of UGT1A1 TA indel.
Patients undergo blood collection at baseline and periodically during study for pharmacokinetics, dihydropyridine deaminase enzyme assay, and pathway expression analysis.
After completion of study treatment, patients are followed every 6 weeks for up to 2 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Biopsy confirmed diagnosis of gastrointestinal cancer
Measurable or evaluable (non-measurable) disease
Measurable disease is defined as ≥ 1 lesion that can be accurately measured (longest diameter to be recorded) as ≥ 2.0 cm with conventional techniques or as ≥ 1.0 cm with spiral CT scan
The following are considered non-measurable disease:
PATIENT CHARACTERISTICS:
Inclusion criteria
Exclusion criteria
PRIOR CONCURRENT THERAPY:
More than 2 weeks since completion of prior radiotherapy
United States, Minnesota | |
Mayo Clinic Cancer Center | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623 |
Principal Investigator: | Robert McWilliams, MD | Mayo Clinic |
Study ID Numbers: | CDR0000592931, MAYO-MC064G |
Study First Received: | April 4, 2008 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00654160 History of Changes |
Health Authority: | Unspecified |
stage IIIB anal cancer stage IV anal cancer recurrent anal cancer carcinoma of the appendix stage III colon cancer stage IV colon cancer recurrent colon cancer stage III rectal cancer stage IV rectal cancer recurrent rectal cancer stage III esophageal cancer stage IV esophageal cancer recurrent esophageal cancer recurrent extrahepatic bile duct cancer unresectable extrahepatic bile duct cancer |
unresectable gallbladder cancer recurrent gallbladder cancer stage III gastric cancer stage IV gastric cancer recurrent gastric cancer metastatic gastrointestinal carcinoid tumor recurrent gastrointestinal carcinoid tumor regional gastrointestinal carcinoid tumor gastrointestinal stromal tumor advanced adult primary liver cancer localized unresectable adult primary liver cancer recurrent adult primary liver cancer stage II pancreatic cancer stage III pancreatic cancer stage IV pancreatic cancer |
Gallbladder Diseases Liver Diseases Rectal Neoplasms Pancreatic Neoplasms Colonic Diseases Anal Cancer Rectal Diseases Ileal Diseases Duodenal Neoplasms Neuroepithelioma Endocrine Gland Neoplasms Carcinoid Syndrome Digestive System Neoplasms Endocrine System Diseases Esophageal Cancer |
Malignant Carcinoid Syndrome Camptothecin Carcinoma Neuroectodermal Tumors Bile Duct Diseases Esophageal Disorder Fluorouracil Gastrointestinal Neoplasms Pancreatic Diseases Carcinoid Tumor Stomach Cancer Bile Duct Neoplasms Esophageal Diseases Gallbladder Neoplasms Antineoplastic Agents, Phytogenic |
Gallbladder Diseases Liver Diseases Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Rectal Neoplasms Pancreatic Neoplasms Physiological Effects of Drugs Colonic Diseases Rectal Diseases Ileal Diseases Duodenal Neoplasms Neoplasms by Site Therapeutic Uses Endocrine Gland Neoplasms Digestive System Neoplasms |
Endocrine System Diseases Malignant Carcinoid Syndrome Camptothecin Carcinoma Neuroectodermal Tumors Neoplasms Bile Duct Diseases Fluorouracil Gastrointestinal Neoplasms Pancreatic Diseases Carcinoid Tumor Bile Duct Neoplasms Esophageal Diseases Gallbladder Neoplasms Antineoplastic Agents, Phytogenic |